Status:
WITHDRAWN
Gentian Violet Treatment for Hidradenitis Suppurativa
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey respons...
Detailed Description
Hidradenitis suppurativa (HS) is a chronic disease of the folliculopilosebaceous unit, often found in intertriginous areas of the body. The pain and impairment of HS leads patients to report a decreas...
Eligibility Criteria
Inclusion
- Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month.
Exclusion
- Exclusion criteria include children, absent HS lesions at the time of clinic, and cognitive/physical impairments that would make them unable to assess quality of life factors of the survey.
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04388163
Start Date
August 1 2025
End Date
December 1 2026
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest School of Medicine
Winston-Salem, North Carolina, United States, 27157